BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

29209

532890

TAKE

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

TAKE SOLUTIONS LTD performance

Today’s low

Today’s high

₹ 8.03 ₹ 8.03
₹ 8.03

52 week low

52 week high

₹ 6.51 ₹ 24.40
₹ 8.03

Open Price

₹ 8.03

Prev. Close

₹ 8.20

Volume (Shares)

10020.00

Total traded value

₹ .80

Upper Circuit

₹ 8.36

Lower Circuit

₹ 8.03

info

TAKE SOLUTIONS LTD Share Price Update

As of the latest trading session, TAKE SOLUTIONS LTD share price is currently at ₹ 8.03, which is down by ₹ -0.17 from its previous closing. Today, the stock has fluctuated between ₹ 8.03 and ₹ 8.03. Over the past year, TAKE SOLUTIONS LTD has achieved a return of -64.65 %. In the last month alone, the return has been 16.80 %. Read More...

TAKE SOLUTIONS LTD fundamentals


  • Market cap (Cr)

    117.41

  • P/E Ratio (TTM)

    -0.44

  • Beta

    0.81

  • Book Value / share

    1.35

  • Return on equity

    0.00%

  • EPS (TTM)

    0.00

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    0.94

info icon alternate text
  • Market cap (Cr)

    118.58

  • P/E Ratio (TTM)

    -0.43

  • Beta

    0.77

  • Book Value / share

    1.35

  • Return on equity

    0.00%

  • EPS (TTM)

    0.00

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    0.94

info icon alternate text

TAKE SOLUTIONS LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 0.00
Operating Expense 0.99
Net Profit 0.94
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.06
EBITDA 2.15
Effective Tax Rate (%) 0.00
Particulars SEP 2024 (Values in Cr)
Revenue 0.00
Operating Expense 1.06
Net Profit -27.57
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -1.86
EBITDA -1.24
Effective Tax Rate (%) 4.25
Particulars JUN 2024 (Values in Cr)
Revenue 0.90
Operating Expense 0.78
Net Profit -47.88
Net Profit Margin (%) -5320.00
Earnings Per Share (EPS) -3.24
EBITDA -0.17
Effective Tax Rate (%) -17.64
Particulars MAR 2024 (Values in Cr)
Revenue 0.00
Operating Expense 8.12
Net Profit -201.49
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -13.62
EBITDA -68.47
Effective Tax Rate (%) -0.87
Particulars DEC 2023 (Values in Cr)
Revenue 0.00
Operating Expense 1.78
Net Profit -4.65
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -0.31
EBITDA -0.79
Effective Tax Rate (%) -334.57
Particulars MAR 2024 (Values in Cr)
Revenue 5.42
Operating Expense 16.39
Net Profit -207.25
Net Profit Margin (%) -3823.80
Earnings Per Share (EPS) -14.01
EBITDA -69.60
Effective Tax Rate (%) -5.64
Particulars MAR 2023 (Values in Cr)
Revenue 56.23
Operating Expense 55.15
Net Profit 4.29
Net Profit Margin (%) 7.62
Earnings Per Share (EPS) 0.29
EBITDA 6.43
Effective Tax Rate (%) 8.72
Particulars MAR 2022 (Values in Cr)
Revenue 18.00
Operating Expense 32.89
Net Profit -477.17
Net Profit Margin (%) -2650.94
Earnings Per Share (EPS) -32.26
EBITDA -1.23
Effective Tax Rate (%) -86.18
Particulars MAR 2021 (Values in Cr)
Revenue 10.72
Operating Expense 19.52
Net Profit 7.79
Net Profit Margin (%) 72.66
Earnings Per Share (EPS) 0.53
EBITDA -5.36
Effective Tax Rate (%) 17.53
Particulars MAR 2020 (Values in Cr)
Revenue 2.47
Operating Expense 21.61
Net Profit 7.74
Net Profit Margin (%) 313.36
Earnings Per Share (EPS) 0.52
EBITDA 9.11
Effective Tax Rate (%) -11.52
Particulars MAR 2024 (Values in Cr)
Book Value / Share -0.61
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.84
EBITDA Margin -17.15
Particulars MAR 2023 (Values in Cr)
Book Value / Share 7.43
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.36
EBITDA Margin -5.72
Particulars MAR 2022 (Values in Cr)
Book Value / Share 12.38
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.44
EBITDA Margin 3.64
Particulars MAR 2021 (Values in Cr)
Book Value / Share 76.92
ROE % -17.24
ROCE % -9.17
Total Debt to Total Equity 0.40
EBITDA Margin -7.90
Particulars MAR 2020 (Values in Cr)
Book Value / Share 107.74
ROE % -0.71
ROCE % 1.36
Total Debt to Total Equity 0.33
EBITDA Margin 8.82
Particulars MAR 2024 (Values in Cr)
Book Value / Share 6.45
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -390.04
Particulars MAR 2023 (Values in Cr)
Book Value / Share 20.47
ROE % 1.75
ROCE % 2.17
Total Debt to Total Equity 0.01
EBITDA Margin 21.22
Particulars MAR 2022 (Values in Cr)
Book Value / Share 20.17
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 21.78
Particulars MAR 2021 (Values in Cr)
Book Value / Share 52.39
ROE % -0.78
ROCE % -0.90
Total Debt to Total Equity 0.00
EBITDA Margin -50.09
Particulars MAR 2020 (Values in Cr)
Book Value / Share 51.77
ROE % 1.01
ROCE % 0.97
Total Debt to Total Equity 0.00
EBITDA Margin 371.26
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.94
Total Assets 88.10
Total Liabilities 88.10
Total Equity -8.87
Share Outstanding 146224984
Price to Book Ratio 3.21
Return on Assets (%) -135.76
Return on Capital (%) -626.81
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 11.17
Total Assets 224.37
Total Liabilities 224.37
Total Equity 108.60
Share Outstanding 146224984
Price to Book Ratio 0.66
Return on Assets (%) -44.68
Return on Capital (%) -70.68
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 29.49
Total Assets 1223.09
Total Liabilities 1223.09
Total Equity 180.62
Share Outstanding 146224984
Price to Book Ratio 1.44
Return on Assets (%) -63.95
Return on Capital (%) -346.21
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 39.29
Total Assets 1844.58
Total Liabilities 1844.58
Total Equity 1124.30
Share Outstanding 146224984
Price to Book Ratio 0.86
Return on Assets (%) -24.50
Return on Capital (%) -28.71
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 45.49
Total Assets 2483.25
Total Liabilities 2483.25
Total Equity 1585.39
Share Outstanding 146224984
Price to Book Ratio 0.77
Return on Assets (%) -0.49
Return on Capital (%) -0.59
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.59
Total Assets 119.17
Total Liabilities 119.17
Total Equity 95.41
Share Outstanding 147934000
Price to Book Ratio 3.21
Return on Assets (%) -173.90
Return on Capital (%) -217.21
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 6.53
Total Assets 318.69
Total Liabilities 318.69
Total Equity 302.77
Share Outstanding 147934000
Price to Book Ratio 0.66
Return on Assets (%) 1.34
Return on Capital (%) 1.42
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.77
Total Assets 311.76
Total Liabilities 311.76
Total Equity 298.44
Share Outstanding 147934000
Price to Book Ratio 1.44
Return on Assets (%) -153.05
Return on Capital (%) -159.89
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 11.50
Total Assets 786.26
Total Liabilities 786.26
Total Equity 775.07
Share Outstanding 147934000
Price to Book Ratio 0.86
Return on Assets (%) 0.99
Return on Capital (%) 1.01
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1.03
Total Assets 776.29
Total Liabilities 776.29
Total Equity 765.82
Share Outstanding 147930000
Price to Book Ratio 0.77
Return on Assets (%) 0.99
Return on Capital (%) 1.01
Particulars MAR 2024 (Values in Cr)
Net Income -118.39
Cash from Operations 8.81
Cash from Investing -7.46
Cash from Financing -11.73
Net change in Cash -9.88
Free Cash Flow 16.73
Particulars MAR 2023 (Values in Cr)
Net Income -98.67
Cash from Operations 21.47
Cash from Investing -2.12
Cash from Financing -35.72
Net change in Cash -17.83
Free Cash Flow 53.87
Particulars MAR 2022 (Values in Cr)
Net Income -771.01
Cash from Operations 51.15
Cash from Investing -30.64
Cash from Financing -54.51
Net change in Cash -55.53
Free Cash Flow 82.37
Particulars MAR 2021 (Values in Cr)
Net Income -435.62
Cash from Operations 154.88
Cash from Investing -56.98
Cash from Financing -83.94
Net change in Cash -5.69
Free Cash Flow 158.03
Particulars MAR 2020 (Values in Cr)
Net Income -12.91
Cash from Operations 263.51
Cash from Investing -235.68
Cash from Financing 20.53
Net change in Cash -4.00
Free Cash Flow 421.12
Particulars MAR 2024 (Values in Cr)
Net Income -203.24
Cash from Operations -3.83
Cash from Investing -1.01
Cash from Financing -0.23
Net change in Cash -5.72
Free Cash Flow -3.71
Particulars MAR 2023 (Values in Cr)
Net Income 4.69
Cash from Operations 31.32
Cash from Investing -22.37
Cash from Financing -0.83
Net change in Cash 3.68
Free Cash Flow 31.32
Particulars MAR 2022 (Values in Cr)
Net Income -474.44
Cash from Operations 32.76
Cash from Investing -40.18
Cash from Financing -1.10
Net change in Cash -8.71
Free Cash Flow 32.80
Particulars MAR 2021 (Values in Cr)
Net Income 6.51
Cash from Operations -2.53
Cash from Investing 13.41
Cash from Financing -0.25
Net change in Cash 10.51
Free Cash Flow -2.51
Particulars MAR 2020 (Values in Cr)
Net Income 6.93
Cash from Operations -13.73
Cash from Investing 21.78
Cash from Financing -8.25
Net change in Cash -1.37
Free Cash Flow -13.73
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 6992.60 76.74 13.41 100542.86 5690.80 / 7545.10
FORTIS MALAR HOSPITALS LIMITED 78.74 192.05 4.94 147.57 51.01 / 98.70
SHREE PACETRONIX LTD. 71.00 14.79 1.90 25.56 61.11 / 268.50
TRANSGENE BIOTEK LTD. 3.75 0.00 2.62 28.41 3.22 / 10.84
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 6992.60 83.66 12.27 100542.86 5690.80 / 7545.10
Surlux Diagnostic Ltd 1.40 0.84 0.13 0.49 0.00 / 0.00
CHENNAI MEENAKSHI MULTISPECIAL 31.25 0.00 -16.74 23.34 28.34 / 59.90
KOVAI MEDICAL CENTER & HOSPITA 5584.95 29.60 6.27 6109.94 3750.00 / 6400.00

TAKE SOLUTIONS LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
8.03 -2.07 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 8.40
  • 26 Days 8.50
  • 10 Days 8.50
  • 50 Days 9.40
  • 12 Days 8.40
  • 100 Days 11.50
  • 20 Days 8.40
  • 200 Days 14.30
8.27 PIVOT

First Support

8.13

First Resistance

8.33

Second Support

8.07

Second Resistance

8.47

Third Support

7.93

Third Resistance

8.53

RSI

43.90

ADX

8.40

MACD

-0.09

Williams % R

-60.00

Commodity Channel Index (CCI)

20.41

Date

2025-01-23

Week

162039.00

Same Day

202618.00

Month

102550.00

1 Year

0.81

3 Year

0.95

Over 1 Month

16.80%

down

Over 1 Year

-64.65%

down

Over 3 Months

-30.56%

down

Over 3 Years

-35.02%

down

Over 6 Months

-53.64%

down

Over 5 Years

-32.79%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

TAKE SOLUTIONS LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
0.0%
Promoter Holdings
0.0%
FII
0.0%
DII
0.0%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Take Solutions Pte Limited 7.825345E7 (52.9%) Shareholding of Promoter and Promoter Group
Aakanksha Management Consultancy And Holdings Private Limited 622921.0 (0.42%) Shareholding of Promoter and Promoter Group
Srinivasan H R 135000.0 (0.09%) Shareholding of Promoter and Promoter Group
Asia Global Trading(chennai) Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Esyspro Infotech Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

TAKE SOLUTIONS LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
01 Aug 2019 0.4 Final 03 Aug 2019 Equity shares
22 Feb 2019 0.3 Interim 2 25 Feb 2019 Equity shares
09 Nov 2018 0.3 Interim 1 12 Nov 2018 Equity shares
02 Aug 2018 0.4 Final 04 Aug 2018 Equity shares
02 Aug 2018 0.6 Special 04 Aug 2018 Equity shares
15 Feb 2018 0.3 Interim 2 19 Feb 2018 Equity shares
17 Nov 2017 0.3 Interim 1 20 Nov 2017 Equity shares
03 Aug 2017 0.4 Final 05 Aug 2017 Equity shares
16 Feb 2017 0.3 Interim 17 Feb 2017 Equity shares
17 Nov 2016 0.3 Interim 19 Nov 2016 Equity shares
18 Aug 2016 0.4 Final 20 Aug 2016 Equity shares
17 Feb 2016 0.3 Interim 19 Feb 2016 Equity shares
23 Nov 2015 0.3 Interim 25 Nov 2015 Equity shares
20 Aug 2015 0.4 Final 22 Aug 2015 Equity shares
18 Feb 2015 0.3 Interim 20 Feb 2015 Equity shares
25 Nov 2014 0.3 Interim 26 Nov 2014 Equity shares
11 Sep 2014 0.4 Final 13 Sep 2014 Equity shares
11 Feb 2014 0.3 Interim 12 Feb 2014 Equity shares
21 Nov 2013 0.3 Interim 22 Nov 2013 Equity shares
29 Aug 2013 0.4 Final 31 Aug 2013 Equity shares
25 Feb 2013 0.3 Interim 2 26 Feb 2013 Equity shares
23 Nov 2012 0.3 Interim 26 Nov 2012 Equity shares
30 Aug 2012 1.0 Final 01 Sep 2012 Equity shares
17 Aug 2011 1.0 Final 20 Aug 2011 Equity shares
25 Aug 2010 0.2 Final 27 Aug 2010 Equity shares
18 Aug 2009 0.2 Final 21 Aug 2009 Equity shares
30 Jul 2008 2.0 Final 01 Aug 2008 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
18 Sep 2008 10.0 1.0 25 Sep 2008
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
01 Aug 2019 0.4 Final 03 Aug 2019 Equity shares
22 Feb 2019 0.3 Interim 2 25 Feb 2019 Equity shares
09 Nov 2018 0.3 Interim 1 12 Nov 2018 Equity shares
02 Aug 2018 0.4 Final 04 Aug 2018 Equity shares
02 Aug 2018 0.6 Special 04 Aug 2018 Equity shares
15 Feb 2018 0.3 Interim 2 19 Feb 2018 Equity shares
17 Nov 2017 0.3 Interim 1 20 Nov 2017 Equity shares
03 Aug 2017 0.4 Final 05 Aug 2017 Equity shares
16 Feb 2017 0.3 Interim 17 Feb 2017 Equity shares
17 Nov 2016 0.3 Interim 19 Nov 2016 Equity shares
18 Aug 2016 0.4 Final 20 Aug 2016 Equity shares
17 Feb 2016 0.3 Interim 19 Feb 2016 Equity shares
23 Nov 2015 0.3 Interim 25 Nov 2015 Equity shares
20 Aug 2015 0.4 Final 22 Aug 2015 Equity shares
18 Feb 2015 0.3 Interim 20 Feb 2015 Equity shares
25 Nov 2014 0.3 Interim 26 Nov 2014 Equity shares
11 Sep 2014 0.4 Final 13 Sep 2014 Equity shares
11 Feb 2014 0.3 Interim 12 Feb 2014 Equity shares
21 Nov 2013 0.3 Interim 22 Nov 2013 Equity shares
29 Aug 2013 0.4 Final 31 Aug 2013 Equity shares
25 Feb 2013 0.3 Interim 2 26 Feb 2013 Equity shares
23 Nov 2012 0.3 Interim 26 Nov 2012 Equity shares
30 Aug 2012 1.0 Final 01 Sep 2012 Equity shares
17 Aug 2011 1.0 Final 20 Aug 2011 Equity shares
25 Aug 2010 0.2 Final 27 Aug 2010 Equity shares
18 Aug 2009 0.2 Final 21 Aug 2009 Equity shares
30 Jul 2008 2.0 Final 01 Aug 2008 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
18 Sep 2008 10.0 1.0 25 Sep 2008

TAKE SOLUTIONS LTD Share Price

Take Solutions Limited was incorporated on December 20, 2000. The Company has been promoted by a team of domain experts in the supply chain management sector of the software industry.

TAKE Solutions delivers domain-intensive services and solutions in Life Sciences, Software and Information Technology. In the fast-growing Life Sciences space, the Company offers clients a unique combination of full-service Clinical, Regulatory and Safety services backed by unique technology expertise. Its range of services span from clinical trials to regulatory submissions to post-marketing safety, all backed by insights derived through proprietary industry networks forums. With a team of leading Life Sciences experts, best-in-class systems and processes, and bespoke, industry-specific technology and analytics, the Company delivers successful outcomes for clients. Its global roster of clients includes large and small innovator biopharmaceutical companies as well as generics manufacturers. As of March 31, 2024, TAKE Solutions Pte Ltd owned 52.90% of the Company's equity share capital and has the ability to control its operating and financial policies.

In Supply Chain Management, TAKE through its subsidiaries focuses on niche engineering services, supply chain collaboration and product re-engineering. Its IP-led approach enables clients to automate supply chain processes, track, trace & control at item level, mandate supplier compliance, and streamline material & shipment movement, and thus optimize their processes.

Pursuant to a Scheme of Amalgamation, a company namely, Millennium Infocomm Limited was merged with Company w.e.f. January 1, 2003 i.e. the Appointed Date and the Scheme of Amalgamation came into effect on February 23, 2004.

On February 7 2003, the company has acquired the divisions/softwares of iStartWeb Private Limited and MSIPL. The division of iStartWeb Private Limited, dealt with BPM, workflow management, application and information integration. The division of MSIPL had capabilities in secondary sales management software.

In December 2003, the company has acquired fifty-one (51%) of the equity share capital of Megatrends Limited but subsequently on April 5, 2005 the company has divested equity fully in Megatrends and this company ceased to be our subsidiary.

On November 20, 2004, the company has incorporated a wholly owned Subsidiary in the Kingdom of Bahrain by the name of TAKE Solutions Gulf W.L.L. This Subsidiary has enabled to foray in the Middle East markets for marketing SCM suite of products. However, TAKE Solutions Gulf W.L.L. has now been voluntarily liquidated by the Company w.e.f. January 22, 2007.

In the year 2004-2005, the company has developed a suite of products across the SCM vertical, which enabled to deliver customized business solutions and support services at shrink-wrap speeds to clients.

In December 2005, the company has acquired majority stake in the equity of TAKE Inc. then a subsidiary company of TAKE Solutions Pte Limited (one of our Promoters). In March 2006, the company has acquired the entire shareholding of TAKE Inc. USA and thereby Company forayed into the US markets. The acquisition also added a new vertical i.e. the Life Sciences Space known as Life Sciences Technology Solutions' having a suite of products under the brand umbrella 'OneClinical'. In 2006, TAKE Inc launched the software product PharmaReady in the Life Sciences space. TAKE Inc. further has a subsidiary namely Applied Clinical Intelligence L.L.C.

On 29th March 2006, the company has acquired 58.06% in the equity of Autopartsasia Private Limited, which is a 100% EOU in India. This acquisition enabled to extend SCM model in the automotive space of the industry.

On 31st March 2006, the company has acquired 97.75% in the equity of Millennium Business Solutions (Sdn) Bhd., Malaysia from Millenium Business Solutions Private Limited, India. By way of this acquisition company has forayed into the South East Asian market for marketing SCM suite of products. The company has entered into a Shareholders Agreement dated June 1, 2006 with United Integrated Sdn Bhd, Malaysia for converting this company into a joint venture wherein Company shall hold fifty one percent (51%) equity capital and the rest will be held by United Integrated Sdn Bhd, Malaysia. Pursuant this agreement, the name of the company has been changed to TAKE United Sdn Bhd w.e.f. July 7, 2006. The conversion of the company into a joint venture has not yet been given effect to.

In March 2007, the company has acquired the entire share capital of CMNK Consultancy & Services Private Limited. In June 2007, the company has acquired ClearOrbit Inc. USA, a Delaware Corporation; through USA based subsidiary TAKE Inc. ClearOrbit is now the wholly owned subsidiary of TAKE Solutions Inc.

During FY 2015, TAKE 10 Solutions Private Limited, India was divested and TAKE Intellectual Properties Management Inc., USA was merged with its parent company Navitas Inc, USA.

During the year 2018, the Company allotted 14,697,200 equity shares of Rs 1 each at an issue price of Rs 170.10 per equity share (including a Share Premium of Rs 169.10 per share) on Preferential basis to TAKE Solutions Pte Ltd. (Promoter of the Company) on March 22, 2018 after obtaining the necessary approvals, including In-Principle approvals from both National Stock Exchange and Bombay Stock Exchange.

During the year 2018, the Company disinvested its entire stake held in Towell TAKE Solutions LLC; Muscat (Joint Venture with Towell) on March 28, 2018 for a consideration of USD 2,000,000. Further the step down subsidiaries under Towell TAKE Investments LLC, Muscat (Towell TAKE Solutions LLC, Muscat , TAKE Solutions MEA Limited, Dubai and Mirnah Technologies Systems Limited, Saudi Arabia) also got disinvested in the process.

During FY 2018, the Company had given loan amounting to Rs 573.15 million to its wholly owned subsidiary M/s. Ecron Acunova Limited (f.k.a. Manipal Acunova Limited) and Rs 208.23 million to TAKE Solutions Global Holdings PTE Ltd.

In FY18, TAKE launched an ICH E6 (R2) Readiness Assessment Framework to help industry players become proactively compliant with the latest requirements to run successful clinical trials. To augment its breadth of knowledge and deepen expertise, the Company initiated the institution of a Medical & Scientific Advisory Board. It further leveraged its domain knowledge and technology expertise to launch OneClinical, an eClinical platform to the market. OneClinical delivers near real-time, high-quality data and optimizes clinical trials. Proven across a variety of global trials, the platform offers short setup time with low fixed costs, and provides global accessibility with near real-time data analytics and visualizations.

In FY 2018, the Engineering Services sub-vertical added another offering that enables compliance across the industry. The Green Check Software Platform helps companies assess their supply chains to ensure they meet the requirement of the Safe Drinking Water and Toxic Enforcement Act, also known as Proposition 65, of the State of California, USA.

In FY 2017-18, TAKE invested in its infrastructure across geographies. The Company inaugurated a state-of-the-art, 80-bedded clinical facility in Chennai to cater the growing demand for high quality clinical trials. It expanded the facilities in Bangalore, Princeton and Bogota to take advantage of exciting market opportunities across Asia, Europe and North and South America.

During Q4 FY 2018, one of the Supply Chain subsidiaries of the Company, Towell TAKE Investments LLC was disinvested.

During the year, Company disposed its supply chain unit, TAKE Supply Chain in Austin USA held by Navitas Inc, a wholly owned subsidiary, to ESM Capital, LLC, USA on September 28, 2019, for a consideration of USD 3.25 million.

The Company acquired two US based entities namely KAI Holdings Inc, a CRO & health research company and Dataceutics Holdings Inc, a specialty Clinical Functional Service provider for a consideration of USD 27 million and USD 45 million respectively in FY 2019.

KAI Holdings Inc and Dataceutics Holdings Inc. merged with Navitas Inc, USA and TAKE Innovations Inc, USA, respectively with effect from May 06, 2019.In FY 2019, the Company however, re-classified its business activity from Computer Programming, Consultancy and Related Activities to Scientific Research and Development, so as to represent the main area of activity of the Company.

Parent organization MNC Associate
NSE symbol TAKE
Founded 2000
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Take Solutions Ltd?

Answer Field

The share price of Take Solutions Ltd for NSE is ₹ 8.03 and for BSE is ₹ 8.11.

What is the Market Cap of Take Solutions Ltd?

Answer Field

The market cap of Take Solutions Ltd for NSE is ₹ 1,17.41 Cr. and for BSE is ₹ 1,18.58 Cr. as of now.

What is the 52 Week High and Low of Take Solutions Ltd?

Answer Field

The 52 Week High and Low of Take Solutions Ltd for NSE is ₹ 24.40 and ₹ 6.51 and for BSE is ₹ 24.25 and ₹ 6.70.

How to Buy Take Solutions Ltd share?

Answer Field

You can trade in Take Solutions Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Take Solutions Ltd?

Answer Field

The 1 year returns on the stock has been -64.65%.

What is the Current Share Price of Take Solutions Ltd?

Answer Field

Take Solutions Ltd share price is for NSE ₹ 8.03 & for BSE ₹ 8.11 as on Apr 30 2025 03:14 PM.

What is the Market Cap of Take Solutions Ltd Share?

Answer Field

The market cap of Take Solutions Ltd for NSE ₹ 1,17.41 & for BSE ₹ 1,18.58 as on Apr 30 2025 03:14 PM.

What is the P/E Ratio of Take Solutions Ltd Share?

Answer Field

As on Apr 30 2025 03:14 PM the price-to-earnings (PE) ratio for Take Solutions Ltd share is -0.44.

What is the PB ratio of Take Solutions Ltd Share?

Answer Field

As on Apr 30 2025 03:14 PM, the price-to-book (PB) ratio for Take Solutions Ltd share is 1.35.

How to Buy Take Solutions Ltd Share?

Answer Field

You can trade in Take Solutions Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Take Solutions Ltd Share on Bajaj Broking App?

Answer Field

To buy Take Solutions Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Take Solutions Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|